Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Ultrasensitive Graphene Biosensors Detect Cancer Risk Biomarker

By Doris Mendieta, Contributing News Editor
Posted on 05 Oct 2014
An ultrasensitive biosensor utilizing the exceptional electronic and thermal properties of graphene has been used to detect molecules that indicate an increased risk of developing cancer.

The biosensor has been shown to be more than five times more sensitive than bioassay tests currently in use, and was able to provide results in a matter of minutes, opening up the possibility of a rapid, point-of-care diagnostic tool for patients.

Bioengineers the University of Swansea (UK) developed a viable biosensor by putting graphene onto a silicon carbide substrate under extremely high temperatures and low pressure to form the basis of the biosensor. More...
They patterned graphene devices, using semiconductor processing techniques, before attaching a number of bioreceptor molecules to the graphene devices. These receptors were able to bind to, or target, a specific molecule present in blood, saliva or urine.

The molecule, 8-hydroxydeoxyguanosine (8-OHdG), is produced when DNA is damaged and, in elevated levels, has been linked to an increased risk of developing several cancers. The team used X-ray photoelectron spectroscopy (VG Scienta; Pleasanton, CA, USA) and Raman spectroscopy (Renishaw, Illinois, IL, USA) to confirm that the bioreceptor molecules had attached to the graphene biosensor once fabricated, and then exposed the biosensor to a range of concentrations of 8-OHdG. When 8-OHdG attached to the bioreceptor molecules on the sensor, there was a notable difference in the graphene channel resistance, which the scientists were able to record.

The graphene sensor was capable of detecting 8-OHdG concentrations as low as 0.1 ng/mL which is almost five times more sensitive compared with enzyme-linked immunosorbent assays (ELISAs). The graphene biosensor was also considerably faster at detecting the target molecules, completing the analysis in a matter of minutes. The potential of the biosensor to diagnose and monitor a whole range of diseases as it is quite simple to substitute the specific receptor molecules on the graphene surface.

Owen Guy, PhD, an associate professor of engineering and coauthor of the study, said, “Graphene has superb electronic transport properties and has an intrinsically high surface-to-volume ratio, which make it an ideal material for fabricating biosensors. Now that we've created the first proof-of-concept biosensor using epitaxial graphene, we will look to investigate a range of different biomarkers associated with different diseases and conditions, as well as detecting a number of different biomarkers on the same chip.” The study was published on September 19, 2014, in the journal 2D Materials.

Related Links:

University of Swansea
VG Scienta  
Renishaw



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.